Contents

Reviews

A Systematic Review and Meta-analysis of the Combination of Vinorelbine and Lapatinib in Patients With Her2-positive Metastatic Breast Cancer. A. STRAVODIMOU, I.A. VOUTSADAKIS (Lausanne, Switzerland; Sault Ste. Marie; Sudbury, ON, Canada) ...............................................................................................................

To Combine or Not Combine: Drug Interactions and Tools for Their Analysis. Reflections from the EORTC-PAMM Course on Preclinical and Early-phase Clinical Pharmacology. B. EL HASSOUNI, G. MANTINI, G. LI PETRI, M. CAPULA, L. BOYD, H.N.W. WEINSTEIN, A. VALLÉS-MARTI, M.C.M. KOUWENHOVEN, E. GIOVANNETTI, B.A. WESTERMAN, G.J. PETERS (Amsterdam, the Netherlands; Pisa, Italy) ...........................................................................................................................................................

The Role of PEDF in Pancreatic Cancer. D. ANSARI, C. ALTHINI, H. OHLSSON, M. BAUDEN, R. ANDERSSON (Lund, Sweden) ........................................................................................................................................................................................................

The Hippo Signaling Pathway in Pancreatic Cancer. D. ANSARI, H. OHLSSON, C. ALTHINI, M. BAUDEN, Q. ZHOU, D. HU, R. ANDERSSON (Lund, Sweden; Zhejiang; Wenzhou, PR China) .................................................................................................................................

Drug Delivery Systems for Phthalocyanines for Photodynamic Therapy. J. RAK, P. POUCKOVA, J. BENES, D. VETVICKA (Klecany; Prague, Czech Republic) ........................................................................................................................................

From ‘Targeted Therapy’ to Targeted Therapy. G.J. PETERS (Amsterdam, the Netherlands).................................................................................................................................

Regulation of BS69 Expression in Cancers. Y. CHEN, Y.-H. TSAI, S.-H. TSENG (New Taipei; Taoyuan; Taipei, Taiwan, ROC) .................................................................................................................................................................
Editorial Board

P. A. ABRAMSSON, Malmi, Sweden
B. B. AGCARVAL, San Diego, CA, USA
T. AKIMOTO, Kashima, Chiba, Japan
P. Z. ANASTASIASIDIS, Jacksonville, FL, USA
A. ARCHER, San Antonio, TX, USA
J. P. ARMAND, Toulouse, France
V. I. AVRAMIS, Los Angeles, CA, USA
D. T. BAO, Taichung, Taiwan, ROC
G. BAUER, Freiberg, Germany
E. E. BAULIEU, Le Kremlin-Bicêtre, France
E. J. BENZ, Jr., Boston, MA, USA
J. BERGH, Stockholm, Sweden
F. T. BOSMAN, Lausanne, Switzerland
M. BOUVEY, La Jolla, CA, USA
J. BOYD, Miami, FL, USA
G. BRUGA, Monza, Italy
O. S. BRULAND, Oslo, Norway
J. M. BUATTI, Iowa City, IA, USA
M. M. BURGER, Basel, Switzerland
M. CARBONE, Hongkong, HK, USA
C. CARLBERG, Kuopio, Finland
J. CARLSSON, Uppsala, Sweden
A. F. CHAMBERS, London, ON, Canada
P. CHANDRA, Frankfurt am Main, Germany
L. CHENG, Indianapolis, IN, USA
J.-G. CHUNG, Taichung, Taiwan, ROC
R. CLARKE, Washington, DC, USA
E. DE CLEIRCO, Leuven, Belgium
W. DEN OTTER, Amsterdam, The Netherlands
E. P. DIAMANDIS, Toronto, ON, Canada
G. TH. DIAMONDPOULOS, Boston, MA, USA
L. EGEVAD, Stockholm, Sweden
D. W. FELSEH, Stanford, CA, USA
J. A. FERNANDEZ-POL, Chesterfield, MO, USA
I. J. FIDLER, Houston, TX, USA
A. P. FIELDS, Jacksonville, FL, USA
H. FU, Atlanta, GA, USA
B. FUCHS, Zurich, Switzerland
D. FURTH, Innsbruck, Austria
D. FUKUMURA, Boston, MA, USA
G. GABBIANI, Geneva, Switzerland
R. GANAPATHI, Charlotte, NC, USA
A. F. GAZDAR, Dallas, TX, USA
A. GIORDANO, Philadelphia, PA, USA
G. GITSCH, Freiburg, Germany
M. GNANT, Vienna, Austria
R. H. GOLDFARF, Guillford, CT, USA
A. HELLAND, Oslo, Norway
I. HELSON, Quakertown, PA, USA
R. HENRIKSSON, Umeå, Sweden
R. M. HOFFMAN, San Diego, CA, USA
S. C. HANWAR, New York, NY, USA
J. V. JOHANNESSEN, Oslo, Norway
R. JONES, London, UK
B. KAINA, Mainz, Germany
P.-L. KELKOKUMPU-LEHTINEN, Tampere, Finland
D. G. KIEBACK, Schleswig, Germany
R. KLIAPDOR, Hamburg, Germany
H. KOBAYASHI, Bethesda, MD, USA
S. D. KOTTARIDIS, Athens, Greece
G. R. F. KRUEGER, Kölln, Germany
Pat M. KUMAR, Manchester, UK
Shant KUMAR, Mancheser, UK
O. D. LAURM, Bergen, Norway
F. J. LEJEUNE, Lausanne, Switzerland
S. LINDNER, Linköping, Sweden
L. F. LIU, Piscataway, NJ, USA
E. LUNDEGREN, Umeå, Sweden
Y. MAEHARA, Fukuoka, Japan
J. MAHER, London, UK
J. MARESCAUX, Strasbourg, France
J. MARK, Skivde, Sweden
S. S. MARTIN, Baltimore, MD, USA
S. MIRTA, Houston, TX, USA
S. MIYAMOTO, Fukuoka, Japan
S. MONCADA, Manchester, UK
M. MUELLER, Villingen-Schwenningen, Germany
F. M. MUGGA, New York, NY, USA
NAMIKI, Kanazawa, Ishikawa, Japan
N. NARAYANAN, Boca Ratón, FL, USA
K. NILSSON, Uppsala, Sweden
S. PATHAK, Hemel Hempstead, England
J. L. PERSSON, Malmö, Sweden
G. J. PILKINGTON, Portsmouth, UK
C. D. PLATSISOC.php, Northfield, USA
A. POLLIAK, Jerusalem, Israel
D. RADES, Lübeck, Germany
M. RIGAUD, Limoges, France
U. RINGBORG, Stockholm, Sweden
M. ROSELL, Rome, Italy
S.T. ROSEN, Duarte, CA, USA
A. SCHAUER, Gottingen, Germany
M. SCHNEIDER, Wuppertal, Germany
J. SEHOULI, Berlin, Germany
A. SETH, Toronto, ON, Canada
G. V. SHERBET, Newcastle-upon-Tyne, UK
A. SLOMINSKI, Birmingham, AL, USA
G.I. SOMA, Kagawa, Japan
G. S. STEIN, Burlington, VT, USA
T. STIGBRAND, Umeå, Sweden
T. M. THEOPHANIDES, Athens, Greece
P. M. UELAND, Bergen, Norway
H. VAN VLIERBERGHE, Ghent, Belgium
R. G. VILE, Rochester, MN, USA
M. WELLER, Zurich, Switzerland
J. WESTERMARK, Turku, Finland
B. WESTERMARK, Uppsala, Sweden
Y. YEN, Taipei, Taiwan, ROC
M.R. YOUNG, Charleston, SC, USA
B. ZUMOFF, New York, NY, USA
G. J. DELINASIOS, Athens, Greece
Managing Editor: editor@iiar-anticancer.org
Managing Editor: editor@iiar-anticancer.org
MANAGING EDITOR: The International Institute of Anticancer Research (IIAR) is a non-profit organization that promotes and supports research and education in anticancer research. TheIIAR is a member of UICC. For more information about ANTIcancer RESEARCH, IIAR and the Conferences, please visit the IIAR website: www.iiar-anticancer.org
Copyright: On publication of a manuscript in AR, which is a copyrighted publication, the legal ownership of all published parts of the paper passes from the Author(s) to the Journal. Annual Subscription Rates 2018 per volume: Institutional subscription US$ 1,939.00 (online) or US$ 2,277.00 (print & online). Personal subscription US$ 897.00 (online) or US$ 1,277.00 (print & online). Prices include rapid delivery and insurance. The complete previous volumes of ANTIcancer RESEARCH Vol. 1-37, 1981-2017 are available at 30% discount on the above rates. Subscription Orders: Orders can be placed directly with the Publisher. E-mail: subscriptions@iiar-anticancer.org
Advertising: All correspondence and rate requests should be addressed to the Editorial Office.
Book Reviews: Recently published books and journals should be sent to the Editorial Office. Reviews will be published within 2-4 months. Articles in ANTIcancer RESEARCH are regularly indexed in all bibliographic services, including Current Contents (Life Sciences), Science Citation Index, Index Medicus, Biological Abstracts, PubMed, Chemical Abstracts, Excerpta Medica, University of Sheffield Biomedical Information Service, Current Clinical Cancer, AIDS Abstracts, Elsevier Bibliographic Database, EMBASE, Current Contents, GEOBASE, EM Biology, Elsevier BIOMEDBASE, FLUIDEX, World Textiles, Scopus, Progress in Palliative Care, Cambridge Scientific Abstracts, Cancergram (International Cancer Research Data Bank), MEDLINE, Reference Update - RS Inc., PASCAL-CNRS, Inpharma- Reactions (Datastar, BRS), CABS, Immunology Abstracts, Telegen Abstracts, Genetics Abstracts, Nutrition Research Newsletter, Daily Science Abstracts, Current Titles in Dentistry, Inpharma Weekly, BioBase, MedBase, CAB Abstracts/Glbal Health Databases, Investigational Drugs Database, VINITI Abstracts Journal, Leeds Medical Information, PubsHub, Sociedad Iberoamericana de Información Científica (SIC) Data Bases. Obtaining permission to reuse or reproduce our content: AR has partnered with Copyright Clearance Center (CCC) to make it easy to secure permissions to reuse its content. Please visit www.copyright.com and enter the title that you are requesting permission for in the 'Get Permission' search box. For assistance in placing a permission request, Copyright Clearance Center can be contacted directly at: Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA. Phone: +1-978-750-8400. Fax: +1-978-646-8600. E-mail: info@copyright.com.
The Editors and Publishers of ANTIcancer RESEARCH accept no responsibility for the opinions expressed by the contributors or for the content of advertisements appearing therein.
Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Reviews